Floatz logo

DACLIZUMAB

Multiple Sclerosis

Biogenmonoclonal_antibodyPhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Teriflunomide
Sanofi
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB

View all 50 →

Same molecule, other indications

DACLIZUMAB is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)Dormant
BB
Indicative ·
68 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →